Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Joins mRNA COVID-19 Club With Translate Tie-Up

Two-Pronged Approach For A Coronavirus Vaccine

Executive Summary

The French drugmaker has joined the likes of Moderna, BioNTech and CureVac in advancing an mRNA vaccine against the virus that causes COVID-19 that could take the fraction of the time to develop compared with the old egg- and cell-based technology.

You may also be interested in...



Sanofi Calms France's Fears Over COVID-19 Vaccine Access

Paul Hudson has been at the helm of Sanofi for just nine months, but for the last few days his comments about which country will be first in line for the firm's coronavirus vaccines will have reminded him that the Gallic culture runs deep.

Coronavirus Update: Sanofi And GSK Unveil 'Unprecedented' Vaccine Alliance

Plus: Lilly unveils Olumiant COVID-19 study, Samsung and Vir to collaborate on antibody, Korean industry asks for government assistance.

Pfizer and BioNTech To Initiate COVID-19 Vaccine Clinical Trials In April

The two companies announced more details about their COVID-19 vaccine development plan, including a $185m upfront payment and $113m equity investment from Pfizer.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PL032870

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel